A5017659045- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Childhood Cancer Survivors' Quality of Life
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Multiple Myeloma Research and Treatments
- Lung Cancer Research Studies
- Pharmaceutical studies and practices
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
University of Washington
2018-2023
Abstract The presence of measurable residual disease (MRD) in acute lymphoblastic leukemia (ALL) confers a poor prognosis. CD19-targeted immunotherapy is effective against MRD but logistically challenging, potentially toxic, and not applicable to T-cell ALL. We thus hypothesized that inhibition PD-1 with pembrolizumab could also be for MRD, without lineage restriction. primary objective this phase 2 study was evaluate the efficacy patients ALL MRD. Key eligibility criteria included adults B-...
Treatments for adults with newly-diagnosed acute lymphoblastic leukemia (ALL) may be prohibitively toxic and/or resource-intense. To address this, we performed a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH). Imatinib or dasatinib was added Ph + disease; rituximab when CD20+. Fifty-three patients were evaluable: 28 disease, 25 Ph−. All had ≥1 high-risk clinical feature. Measurable residual disease-negativity by multiparameter...
The multikinase inhibitor sorafenib improves event-free survival (EFS) when used with 7 + 3 in adults newly-diagnosed acute myeloid leukemia (AML), irrespective of the FLT3-mutation status. Here, we evaluated adding to cladribine, high-dose cytarabine, granulocyte colony-stimulating factor, and mitoxantrone (CLAG-M) a phase 1/2 trial 81 aged ≤60 years newly diagnosed AML. Forty-six patients were treated 1 escalating doses mitoxantrone. No maximum tolerated dose was reached, regimen including...
Potential involvement of the central nervous system (CNS) by acute lymphoblastic leukemia is typically evaluated a conventional cytospin (CC) cerebrospinal fluid (CSF). Multiparameter flow cytometry (MFC) generally more sensitive and specific than morphology, but data to guide its use versus CC are limited.This study identified 92 patients who had MFC performed on their initial CSF specimen received at least 4 cycles hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone...